Quantum BioPharma Plans Phase 2 Lucid-MS Trial, Unbuzzd Royalties Up to $250M
QNTM•Quantum BioPharma plans a first-in-patient Phase 2 trial for Lucid-MS, a patented therapy addressing nerve damage to prevent multiple sclerosis mobility loss after successful Phase 1 safety testing. The company also earns 7% royalties on U.S. unbuzzd sales until $250 million is paid, then 3% thereafter.
1. Podcast Feature on Lucid-MS and unbuzzd
Quantum BioPharma’s co-founder and executive co-chair discussed Lucid-MS development and unbuzzd growth on a recent company-focused podcast. He emphasized Lucid-MS’s role in targeting nerve damage to restore mobility in multiple sclerosis and highlighted unbuzzd’s market availability in the U.S.
2. Lucid-MS Preclinical Data and Phase 1 Success
Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The therapy completed a Phase 1 safety trial in healthy volunteers and is moving into a first-in-patient Phase 2 study to evaluate efficacy in multiple sclerosis patients.
3. unbuzzd Commercialization and Royalty Structure
unbuzzd is Quantum’s commercial alcohol metabolism product sold in the U.S. under a royalty agreement that yields 7% of sales until $250 million is paid, dropping to 3% thereafter. Quantum retains a 19.84% equity stake in the spin-out company driving these royalties.
